185 related articles for article (PubMed ID: 33335291)
1. Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition.
Kennedy AJ; Sundström L; Geschwindner S; Poon EKY; Jiang Y; Chen R; Cooke R; Johnstone S; Madin A; Lim J; Liu Q; Lohman RJ; Nordqvist A; Fridén-Saxin M; Yang W; Brown DG; Fairlie DP; Dekker N
Commun Biol; 2020 Dec; 3(1):782. PubMed ID: 33335291
[TBL] [Abstract][Full Text] [Related]
2. Structural insight into allosteric modulation of protease-activated receptor 2.
Cheng RKY; Fiez-Vandal C; Schlenker O; Edman K; Aggeler B; Brown DG; Brown GA; Cooke RM; Dumelin CE; Doré AS; Geschwindner S; Grebner C; Hermansson NO; Jazayeri A; Johansson P; Leong L; Prihandoko R; Rappas M; Soutter H; Snijder A; Sundström L; Tehan B; Thornton P; Troast D; Wiggin G; Zhukov A; Marshall FH; Dekker N
Nature; 2017 May; 545(7652):112-115. PubMed ID: 28445455
[TBL] [Abstract][Full Text] [Related]
3. The development of proteinase-activated receptor-2 modulators and the challenges involved.
McIntosh KA; Cunningham MR; Bushell T; Plevin R
Biochem Soc Trans; 2020 Dec; 48(6):2525-2537. PubMed ID: 33242065
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.
Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN
J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555
[TBL] [Abstract][Full Text] [Related]
5. Biased signaling: potential agonist and antagonist of PAR2.
Kakarala KK; Jamil K
J Biomol Struct Dyn; 2016 Jun; 34(6):1363-76. PubMed ID: 26295578
[TBL] [Abstract][Full Text] [Related]
6. Pathway-selective antagonism of proteinase activated receptor 2.
Suen JY; Cotterell A; Lohman RJ; Lim J; Han A; Yau MK; Liu L; Cooper MA; Vesey DA; Fairlie DP
Br J Pharmacol; 2014 Sep; 171(17):4112-24. PubMed ID: 24821440
[TBL] [Abstract][Full Text] [Related]
7. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).
Suen JY; Barry GD; Lohman RJ; Halili MA; Cotterell AJ; Le GT; Fairlie DP
Br J Pharmacol; 2012 Mar; 165(5):1413-23. PubMed ID: 21806599
[TBL] [Abstract][Full Text] [Related]
8. Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.
Yau MK; Liu L; Lim J; Lohman RJ; Cotterell AJ; Suen JY; Vesey DA; Reid RC; Fairlie DP
Bioorg Med Chem Lett; 2016 Feb; 26(3):986-991. PubMed ID: 26725028
[TBL] [Abstract][Full Text] [Related]
9. Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery.
Perry SR; Xu W; Wirija A; Lim J; Yau MK; Stoermer MJ; Lucke AJ; Fairlie DP
J Chem Inf Model; 2015 Jun; 55(6):1181-91. PubMed ID: 26000704
[TBL] [Abstract][Full Text] [Related]
10. Structure and putative signaling mechanism of Protease activated receptor 2 (PAR2) - a promising target for breast cancer.
Kakarala KK; Jamil K; Devaraji V
J Mol Graph Model; 2014 Sep; 53():179-199. PubMed ID: 25173751
[TBL] [Abstract][Full Text] [Related]
11. Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).
Yau MK; Lim J; Liu L; Fairlie DP
Expert Opin Ther Pat; 2016; 26(4):471-83. PubMed ID: 26936077
[TBL] [Abstract][Full Text] [Related]
12. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells.
Jiang Y; Yau MK; Lim J; Wu KC; Xu W; Suen JY; Fairlie DP
J Pharmacol Exp Ther; 2018 Feb; 364(2):246-257. PubMed ID: 29263243
[TBL] [Abstract][Full Text] [Related]
13. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.
Gandhi DM; Majewski MW; Rosas R; Kentala K; Foster TJ; Greve E; Dockendorff C
Bioorg Med Chem; 2018 May; 26(9):2514-2529. PubMed ID: 29685684
[TBL] [Abstract][Full Text] [Related]
15. An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats.
Lohman RJ; Cotterell AJ; Barry GD; Liu L; Suen JY; Vesey DA; Fairlie DP
FASEB J; 2012 Jul; 26(7):2877-87. PubMed ID: 22467762
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists.
Cho NC; Cha JH; Kim H; Kwak J; Kim D; Seo SH; Shin JS; Kim T; Park KD; Lee J; No KT; Kim YK; Lee KT; Pae AN
Bioorg Med Chem; 2015 Dec; 23(24):7717-27. PubMed ID: 26631441
[TBL] [Abstract][Full Text] [Related]
17. Toward drugs for protease-activated receptor 2 (PAR2).
Yau MK; Liu L; Fairlie DP
J Med Chem; 2013 Oct; 56(19):7477-97. PubMed ID: 23895492
[TBL] [Abstract][Full Text] [Related]
18. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins.
Sevigny LM; Zhang P; Bohm A; Lazarides K; Perides G; Covic L; Kuliopulos A
Proc Natl Acad Sci U S A; 2011 May; 108(20):8491-6. PubMed ID: 21536878
[TBL] [Abstract][Full Text] [Related]
19. C781, a β-Arrestin Biased Antagonist at Protease-Activated Receptor-2 (PAR2), Displays in vivo Efficacy Against Protease-Induced Pain in Mice.
Kume M; Ahmad A; Shiers S; Burton MD; DeFea KA; Vagner J; Dussor G; Boitano S; Price TJ
J Pain; 2023 Apr; 24(4):605-616. PubMed ID: 36417966
[TBL] [Abstract][Full Text] [Related]
20. Overview of Critical Parameters for the Design and Execution of a High-Throughput Screen for Allosteric Ligands.
Alt A
Curr Protoc Pharmacol; 2016 Sep; 74():9.20.1-9.20.23. PubMed ID: 27636112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
